XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENTED INFORMATION
 3 Months Ended
Mar. 31, 2022
SEGMENTED INFORMATION  
NOTE 12 - SEGMENTED INFORMATION

NOTE 12 - SEGMENTED INFORMATION

 

At March 31, 2022, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

 

 

 

 

BioNexus Gene Lab Corp.

a Wyoming company

 

 

 

 

 

 

 

 

 

 

 

 

100% owned

 

 

100% owned

 

 

Bionexus Gene Lab

Sdn. Bhd.,

a Malaysian company

 

 

Chemrex Corporation

Sdn. Bhd.,

a Malaysian company

 

At March 31, 2022, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

 

For the quarter ended March 31, 2022, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

 

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Three months ended March 31, 2022

 

REVENUE

 

$24,269

 

 

$3,004,676

 

 

$-

 

 

$3,028,945

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(30,832)

 

 

(2,664,574)

 

 

-

 

 

 

(2,695,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS (LOSS)/PROFIT

 

 

(6,563)

 

 

340,102

 

 

 

-

 

 

 

333,539

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

2,076

 

 

 

44,306

 

 

 

12

 

 

 

46,394

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(21,248)

 

 

(297,769)

 

 

(26,225)

 

 

(345,242)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(799)

 

 

(2,527)

 

 

-

 

 

 

(3,326)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(26,534)

 

 

84,112

 

 

 

(26,213)

 

 

31,365

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

(14,299)

 

 

-

 

 

 

(14,299)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$(26,534)

 

$69,813

 

 

$(26,213)

 

$17,066

 

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Three months ended March 31, 2021

 

REVENUE

 

$97,363

 

 

$3,351,796

 

 

$-

 

 

$3,449,159

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(67,707)

 

 

(2,798,887)

 

 

-

 

 

 

(2,866,594)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

29,656

 

 

 

552,909

 

 

 

-

 

 

 

582,565

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

763

 

 

 

61,625

 

 

 

-

 

 

 

62,388

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(22,511)

 

 

(233,152)

 

 

(47,188)

 

 

(302,851)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,207)

 

 

(2,151)

 

 

-

 

 

 

(3,358)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX

 

 

6,701

 

 

 

379,231

 

 

 

(47,188)

 

 

338,744

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET PROFIT/(LOSS)

 

$6,701

 

 

$379,231

 

 

$(47,188)

 

$338,744

 

 

 

 

As of March 31, 2022 and December 31, 2021

 

 

 

Total Assets

 

 

 Total Liabilities

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BGLC & Bionexus

 

$1,109,804

 

 

$1,167,214

 

 

$125,696

 

 

$121,586

 

Chemrex

 

 

8,065,618

 

 

 

8,407,176

 

 

 

1,921,657

 

 

 

2,273,025

 

TOTAL

 

 

9,175,422

 

 

 

9,574,390

 

 

 

2,047,353

 

 

 

2,394,611